Connect with us

Cannabis News

Massachusetts Governor Signs Bill Doubling Legal Marijuana Possession Limit And Revising Industry Rules

Published

on

The governor of Massachusetts has signed a bill double the legal limit for adult marijuana possession and revise the regulatory framework for the state’s adult cannabis market.

Gov. Maura Healey (D) approved the legislation Sunday, about a week and a half after lawmakers sent it to her desk in unanimous House and Senate votes.

“The cannabis industry is an important part of the Massachusetts economy: it supports jobs and local businesses and generates revenue for cities and towns,” Healey said in a press release. “It is important that we are doing everything we can to ensure that this industry is set up to succeed and remain competitive in this growing market. I am grateful to the Legislature for their leadership on this critical reform project.”

A bicameral conference committee spent months working on provisions of the legislation after the two chambers passed different versions last year, and the committee approved the compromise approach on Monday.

“With the governor’s signature today, our legislature takes an important step toward making the cannabis industry here in Massachusetts more profitable, profitable and competitive for business owners and consumers,” said Sen. Adam Gómez (D), who chaired the bicameral panel. “This legislation strengthens the Cannabis Regulatory Commission’s oversight by making smart updates that help small businesses, improve accountability, and ensure consumers can safely and legally access cannabis.”

“By clarifying shipping and advertising rules, increasing accounts receivable transparency, increasing purchase amounts and modernizing licensing limits, we’re building a more stable and fairer cannabis market for our state and I’m proud of our body for prioritizing reform this session,” he said.

Rep. Daniel M. Donahue (D), who also chaired the conference committee and co-chairs the Joint Committee on Cannabis Policy with Gómez, said he is “delighted” that the legislation became law.

“These reforms represent a new commitment to ensuring a safe, equitable and prosperous future for the Commonwealth’s legalized cannabis industry,” he said. “I look forward to working with the administration through their implementation.”

Among the revisions to the state’s cannabis law is a section that increases the personal possession limit of marijuana from one ounce to two. Colorado enacted the same reform in 2021 after the state’s cannabis market matured.

H.5350 reduces the size of the Cannabis Control Commission (CCC) and overhauls the organization, while also updating the limits on marijuana business licenses.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

According to the versions of both chambers invoiceThe CCC would consist of three members instead of the current five. Conference committee the report it takes provisions of the House measure that has now become law that would allow the governor to make all appointments, with the Senate approach giving the attorney general one of the appointments. According to the previous law, the treasurer also had a role in appointing committee members, but this will no longer be the case.

The proposal calls for one member of the CCC to have a background in social justice, while the other two commissioners have a background in public health, public safety, social justice, consumer regulation or the production and distribution of cannabis.

The new law also increases the number of licenses a single entity can hold from three to six, and also raises from 10 percent to 20 percent the threshold for how much of a company’s equity is considered property to count toward the license cap. It also removes a current requirement that medical cannabis operators be vertically integrated to simultaneously cultivate, manufacture and sell marijuana.

It also empowers regulators to choose dispensaries to advertise sales, discounts and customer loyalty programs at retail locations and via email, and specifies that marijuana dispensary operators can deliver to any municipality unless local officials proactively ban cannabis businesses and stop delivery.

The measure creates a new portal for reporting illegal behavior and directs regulators to create a list of cannabis companies that have not paid their debts to other operators for more than 60 days and prevents regulators from doing business with other operators until the debts are settled.

The legislation also requires regulators to study and report on hemp-derived products, the public health impacts of cannabis, tax policy and workplace safety regulations.

Before the governor signed the bill, the CCC published guidance on the immediate effect of the new law.

After signing the bill on Sunday, CCC Executive Director Travis Ahern he said “During this transition, the organization will remain focused on its primary mission of regulating a safe and fair cannabis industry for Massachusetts consumers, patients, employers and taxpayers.”

Cannabis regulation reform has come into effect after state marijuana businesses filed a lawsuit aimed at blocking it. initiative to roll back the legalization law approved by state voters from reaching the November vote.

If approved, the state would not return to general prohibition; rather, it would repeal the commercial recreational sales and home cultivation components of the law, while allowing adults 21 and older to possess one ounce of cannabis for personal use.

Possession of more than one ounce but less than two ounces would effectively be decriminalized, with violators facing a $100 fine. Adults can also continue to gift cannabis to each other without payment. The sale of medical marijuana would be legal.

The measure is before the legislature after supporters provided an initial round of signatures last year, and lawmakers have until May 5 to act on the proposal. If they decide not to pass it in the legislature, the campaign would have to go through another round of petitions and get at least 12,429 certified signatures by July 1 to get on the November ballot.

The promoters faced skeptical questions from lawmakers at a hearing of the Joint Committee on Initiative Petitions last month, with several. raising concerns about the motivations behind the anti-marijuana measure and the consequences for consumers and companies.

A Bay State Poll by the University of Hampshire State Opinion Project found that A majority of Massachusetts adults oppose the initiative to repeal the sale and cultivation of marijuana.

Meanwhile, in November, the legislature’s Joint Committee on Cannabis Policy advanced a bill that would have required a study. legal barriers facing first responders who want to use marijuana in compliance with state law.

Regulators should also examine marijuana’s effectiveness in the treatment of anxiety, depression and post-traumatic stress disorder (PTSD). In addition, police and first responders in other jurisdictions will review laws and policies regarding the use of cannabis and “any other matter deemed relevant by the commission.”

The bill was reported when lawmakers in another committee passed separate legislation employment protection for people who use marijuana. Another panel advanced a a bill similar to the employment protections for cannabis in September

Meanwhile, the head of Massachusetts’ marijuana regulatory agency recently suggested measures to effectively recriminalize the sale of recreational cannabis. dangerous tax revenues being used to support substance abuse treatment efforts and other public programs.

To that point, Massachusetts recently achieved another marijuana milestone, officials announced in February that the state has. Over $9 billion in adult cannabis purchases since market launch in 2018.

A report by the Cannabis Control Commission (CCC) found that legalization is achieving one of its main goals: stopping the illegal sale of cannabis as adults move into the regulated market. It shows that among adults who used marijuana in the past year, a staggering 84 percent said they got their cannabis from a licensed source.

Massachusetts lawmakers recently joined a bicameral conference committee to hammer out a deal. double the legal limit for possession of marijuana for adults and reviewing the regulatory framework for the state’s adult cannabis market.

In December, state regulators, too established rules for the halls of social consumption of marijuana.

CCC has recently launched a targeted online platform helping people find work, on-the-job training and networking opportunities in the state’s legal cannabis industry.

Separately, members of parliament are advancing the legislation establishing pilot programs for the regulated therapeutic use of psychedelics.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

Concert Series Specials launched for state medical cannabis patients

Published

on

By











Post Dispensary, Kentucky’s first medical cannabis dispensary, is connecting with patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Madisonville, Hopkinsville and surrounding areas by aligning unique specials with the region’s summer concert calendar. Located at 300 N Main St. in Beaver Dam, minutes from major highways connecting these vibrant cities.

This summer, The Post Dispensary is offering special pricing and incentives for Concert Series Events at the Beaver Dam Amphitheater, SPARKS in the Park 4th of July celebration and surrounding events, such as Owensboro’s ROMP Festival (June 24-27, 2026). Patients can stop by before or after shows for big savings.

“We’re more than just a booty,” said a dispensary representative. “From Owensboro’s world-class ROMP Festival to Beaver Dam’s Amphitheater events, we’re making it convenient and budget-friendly for patients in Owensboro, Henderson, Bowling Green, Elizabethtown, Hartford and beyond to combine our love of music with compassionate care and an affordable product.”

The Post Dispensary hosts regular Patient Guidance events on the second Saturday of every month. These units have professionals on hand to assess patients and issue written certificates at low cost, application support and expert consultations in a welcoming environment. The next Patient Drive aligns perfectly with summer travel patterns, making it easy for patients from Owensboro, Bowling Green, Elizabethtown, Madisonville, Henderson, Madisonville and surrounding towns to plan a trip to Beaver Dam that combines care with community and entertainment.

For more information:
Post-Dispensary
thepostdispensary.com/










Continue Reading

Cannabis News

Missouri GOP Lawmakers Hope Trump’s Psychedelics Order Boosts Efforts To Allow Military Veteran Access In The State

Published

on

By

“Congratulations to President Trump for stepping up and taking the lead on this. PTSD is a killer among veterans.”

By Rebecca Rivas, Missouri Independent

Missouri state representative Dave Griffith has spent the past five years researching how psychedelic-assisted therapy has helped veterans struggling with post-traumatic stress disorder and depression.

His last legislative session in the House ended this May, and he pushed legislation for the last time allow clinical trials of psychedelic-assisted therapy in Missouri. In the final days of the session, the bill stalled in the Missouri Senate after passing the House with overwhelming support.

“I’m not going to be there next year, I’m term-limited,” said Griffith, a Republican who served as chairman of the House Veterans Affairs and Armed Services Committee. “It’s really about passing the torch to a lot of other veterans who are on the Veterans Commission and see the value in that.”

He was hopeful when he saw an announcement The US Department of Veterans Affairs announced last week a new clinical trial to evaluate the safety and effectiveness of methylenedioxymethamphetamine-assisted therapy.or MDMA-assisted therapy. MDMA is a synthetic substance made in a laboratory, according to the department, and is also called “ecstasy” or “molly” in recreational use.

“Congratulations to President Trump for stepping up and taking the lead on this,” said Griffith of Jefferson City. “PTSD is a killer among veterans. If you just listen to the testimony that’s been happening over the last five years in the Missouri House, the life-changing it’s been for them is a compelling reason why something like this works.”

A new trial follows Trump signed an executive order in April, “Expediting Medical Treatment for Serious Mental Illness.” The order aims to increase participation in clinical trials and accelerate innovative research models and drug approvals for psychedelics.

Directs the Secretary of Health and Human Services to allocate at least $50 million to support and collaborate with state governments that “have established or are developing programs to advance psychedelic drugs for serious mental illness.”

Without passing the legislation, Missouri will miss this opportunity, said Republican state representative Matthew Overcast of Ava.

Cloud hoped that Trump’s April order would help “grease the wheels” this year by state Rep. Richard West and state Rep. Richard West who sponsored the state to conduct a study on psilocybin and ibogaine therapy.

“The last couple of months there’s been a lot of feds on things that the states are reluctant to move forward with here,” Overcast said. “So it’s exciting.”

According to the VA’s announcement, the department is involved in 19 other active clinical trials focused on psychedelic therapies for mental health conditions that have received more than $23 million in outside funding.

The new trial, called “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in US Veterans,” will enroll about 80 veterans and compare outcomes between those receiving MDMA-assisted therapy and those receiving the same psychotherapy with an active placebo. VA is coordinating with the US Food and Drug Administration and plans to share trial data with FDA.

The trial will be conducted at the VA Providence Healthcare System, and will recruit veterans from the Providence, Rhode Island, campus in West Haven, Connecticut, and the VA Connecticut Healthcare System.

Trump’s executive order says there have been more than 6,000 veteran suicides per year for more than 20 years, and the current veteran suicide rate is twice that of the adult non-veteran population.

He says people with major depressive disorder and substance abuse disorder, among other serious mental illnesses, may relapse or fail to respond fully to standard medical and psychiatric therapies.

“Despite significant federal investment in research into potential advances in mental health care and treatment, our medical research system has yet to produce approved therapies that promote lasting improvements in the mental health status of the most complex patients,” the order states. “Innovative methods are needed to find long-term solutions for these Americans beyond existing prescription drugs.”

Missouri veterans John and Kara Grady, who own a hemp shop in Rosebud, strongly agree with the statement, they said. And they’d like to see Missouri’s veterans health system participate in clinical trials already underway.

“President Trump is opening up investigations for the veteran community,” said John Grady, “If you look at the numbers … we’ve lost more in the wars with mental health than we’ve lost.”

The lack of movement on psychedelic-assisted therapy legislation is among the reasons why John Grady is running for state representative over Bruce Sassmann in the state’s Republican primary.

“If you don’t agree with Trump on everything, at least he’s addressing this veteran issue right here,” Grady said. “Hopefully, we’ll be able to stop that number, we’ll stop that flow of our precious veterans dying by their own hands because they don’t have treatment.”

This story was first published by the Missouri Independent.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Germany’s medical cannabis imports post first quarterly decline since early 2024

Published

on

By

German imports of medical cannabis flowers fell to 50.5 tonnes in the first quarter of 2026, down from 60.8 tonnes in the previous quarter, the decline from the first quarter of 2024. According to a new EU and UK market update from Whitney Economics.

The drop lands against a year that went backwards. Germany took in more than 2025 tonnes of the product in 2025, more than double the 72,850 kilograms recorded in 2024, and import volumes have risen every year since 2018, when the figure remained below 4,500 kilograms. The first quarter number continues to match the high pace of 2025, which is why the report treats it as an early sign of stabilization rather than a turnaround.

Prices
The volume has not created a stable price. A gram of cannabis in a German pharmacy is approaching 4 euros, while a gram on the illegal market is around 8 euros, reversing the usual relationship between regulated and unregulated supply. The wholesale price is around 2 euros per gram, roughly half the retail price at the pharmacy. Pharmacy prices breached 3.99 euros in November 2025, and the report puts the overall compression close to 25% in two and a half years.

Germany legalized ownership in 2024 and restricted sales to pharmaceutical and telemedicine providers. Two access roads run parallel. Medical cannabis is mainly prescribed through private prescriptions, and recreational cannabis is available through membership of a cannabis association, with 400 licensed cultivation associations across the country, although the exact count varies by source. It is the medical segment that drives market growth, not the recreational segment.

Growth is based on telemedicine
Patients fill out an online questionnaire, receive a prescription from an affiliated physician, and in many cases have their order filled through an integrated pharmacy partner, with delivery within days and, in some cities, within hours. Between 600,000 and 700,000 self-employed consumers are supported by the telemedicine industry, compared to 200,000 to 300,000 medical patients supported by pharmacies. Total imports are now sufficient to supply between 900,000 and one million consumers.

© Philiprowe | Dreamstime

Market exposure
Critics argue that commercial interests risk overshadowing the medical nature of the system, and treatment does not always meet the required standard of control. Legislative initiatives that would tighten the framework are already on the table, including mandatory in-person inquiries and a ban on distribution of mail requests. The likely result of both measures is a significant decline in demand for medical cannabis flowers. Many telemedicine companies are preparing for the opportunity by building networks with local doctors and pharmacies.

Where patients and consumers would go if medical access is curtailed is an open question, as the recreational market lacks a real alternative for patients and cannabis clubs continue to face licensing hurdles at the state level.

Part of the difficulty in reading the market is that import figures say less than they seem. More cannabis is entering the country than ever before, but how much is reaching consumers and what the actual demand is is unclear. Without a nationwide data framework, the market functions as a black box, and excess supply and actual demand are difficult to measure with great precision. Supply has tended to expand faster than the market can absorb, with no forecast to confirm mature demand, and prices have adjusted downward as a result.

Germany has had a signal effect across Europe since the start of its reform, although its model has drawn criticism, with the mixing of medical and recreational consumption a recurring complaint. Countries that have traditionally taken a conservative line, France among them, have gone to a more formalized medical field, under stricter conditions and without adopting the medical flower like Germany.

For more information:
Whitney Economics
Beau Whitney
(503) 724-3084
www.whitneyeconomics.com

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media